Fate Therapeutics Inc (FATE)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$1.13
Buy
$1.15
$0.04 (+3.60%)
Prices updated at 13 Dec 2025, 00:34 EST
| Prices minimum 15 mins delay
Prices in USD
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 64m | 14m | |
| - | - | |
| -191m | -196m | |
| -299.86 | -1,434.52 | |
| -161m | -186m | |
| -172m | -177m | |
| Sales, General and administrative | 81m | 74m |
| Interest expenses | - | - |
| Provision for income taxes | - | - |
| Operating expenses | 254m | 209m |
| Income before taxes | -161m | -186m |
| Net income available to common shareholders | -161m | -186m |
| -1.64 | -1.64 | |
| Net interest income | 17m | 17m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -1.64 | -1.64 |
| Free cash flow per share | -1.8729 | -1.2171 |
| Book value/share | 4.0838 | 3.1803 |
| Debt equity ratio | 0.264268 | 0.244253 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 332m | 292m |
| Current liabilities | 39m | 39m |
| Total capital | 368m | 319m |
| Total debt | 104m | 85m |
| Total equity | 368m | 319m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 506m | 441m |
| Total liabilities | - | - |
| Cash and cash equivalents | 42m | 36m |
| Common stock | 99m | 114m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 77m | 57m |
| Cash dividends paid | - | - |
| -138m | -124m | |
| Investments (gains) losses | 113m | 12m |
| 57m | 46m | |
| Net income | - | - |
| -132m | -123m | |
| -6m | -730,000 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
